Novo Nordisk Presented Real-World Weight Loss Data
Patients saw weight loss after switching from injectable obesity drugs to an oral tablet.
Updated on Sept. 30, 2026 in Weight Loss
Live Poll
Would you prefer taking an oral pill over weekly injections for weight loss treatment?
Novo Nordisk shared real-world study results demonstrating that patients who transitioned from injectable obesity treatments to its oral Wegovy pill experienced significant weight reduction. Participants lost an average of 4% of their body weight over a three-month period.
Why it matters
The shift toward oral medication offers patients improved convenience by eliminating the need for refrigerated injections. This transition aims to simplify long-term obesity management for individuals currently using injectable therapies.
In an analysis of 194 patients with an average starting weight of 221 pounds, 40% achieved 5% or more weight loss after three months. Additionally, the proportion of participants with a body mass index of 30 or higher dropped by more than 21%.
The players
Novo Nordisk
This is a global healthcare company that specializes in the production of diabetes and obesity treatments.
Ro
This is a telehealth company that provides digital health services, including the platform used to analyze the weight loss data.
The details
The study analyzed data from the Ro telehealth platform, showing that 82% of patients reported at least one improvement during treatment and 75% expressed satisfaction with the switch. Novo Nordisk also reported that its experimental drug CagriSema reduced food-related thoughts and targeted harmful abdominal fat in separate studies.
Timeline
September 30, 2026: Novo Nordisk presented the real-world analysis in Milan, Italy.
Early 2027: The expected market launch of the drug CagriSema.
2028: The planned launch of standalone cagrilintide and a higher-dose version of CagriSema.
The Big Picture
This study follows a pattern set by the ongoing development of CagriSema to advance obesity care. It signals a shift in the pharmaceutical strategy to broaden treatment options beyond traditional injectable medications.
Patients may find a more convenient alternative to refrigerated injectables by switching to oral tablets for weight management. Increased satisfaction rates among current users suggest that oral options could improve long-term adherence to prescribed obesity treatments.
The takeaway
The move toward oral medication options represents a significant shift in patient preference for managing obesity. These results indicate that oral pills can offer comparable outcomes to injectables while potentially increasing user satisfaction.
What happens next
Novo Nordisk plans to launch its new obesity drug CagriSema in early 2027, followed by the introduction of standalone cagrilintide and a higher-dose version of CagriSema in 2028.
Further reading
For more information on the latest clinical advancements, visit our Weight Loss section.
Live Poll
Would you prefer taking an oral pill over weekly injections for weight loss treatment?
